Modeling Human Liver Cancer Heterogeneity: Virally Induced Transgenic Models and Mouse Genetic Models of Chronic Liver Inflammation

Marc Ringelhan1, Florian Reisinger2, Detian Yuan2, Achim Weber3, Mathias Heikenwalder2

1 German Center for Infection Research (DZIF), München, 2 Institute of Virology, München, 3 Institute of Surgical Pathology, Zürich
Publication Name:  Current Protocols in Pharmacology
Unit Number:  Unit 14.31
DOI:  10.1002/0471141755.ph1431s67
Online Posting Date:  December, 2014
GO TO THE FULL TEXT: PDF or HTML at Wiley Online Library

Abstract

In addition to being the most common primary liver cancer, hepatocellular carcinoma (HCC) is the second most common cause of cancer‐related death in humans. Treatment options are limited for this chemoresistant cancer, with liver transplantation and surgical intervention in early stages being the most successful treatments. Drug development over the past 15 years has focused on generating mouse models that mimic the human pathology for HCC. This has enabled the laboratory testing of potentially new human therapeutics. Described in this unit are the classification of HCC and an overview of hepatitis virus‐related transgenic and genetically engineered mouse models (GEMMs) that are employed for elucidating the mechanism(s) responsible for the development of HCC, with particular emphasis on genetic, dietary, and environmental factors. © 2014 by John Wiley & Sons, Inc.

Keywords: mouse model; chronic liver inflammation; HCC; liver cancer; modeling human disease

     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Table of Contents

  • Introduction
  • Classifications for Human HCC
  • Mouse Genetic Models Mimicking Chronic Inflammation and Chronic Liver Damage
  • Apoptosis and Proliferation‐Induced HCC
  • Models of NAFLD/NASH‐Driven HCC
  • Models for Virus‐Induced Liver Cancer (Table )
  • HBV‐Related Transgenic Models of HCC
  • HCV‐Related Transgenic Models of HCC
  • Xenograft Mouse Models
  • Challenges in HCC Mouse Models and Future Opportunities
  • Acknowledgements
  • Literature Cited
  • Figures
  • Tables
     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Materials

GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Figures

Videos

Literature Cited

Literature Cited
  Barone, M., Spano, D., D'Apolito, M., Centra, M., Lasalandra, C., Capasso, M., Di Leo, A., Volinia, S., Arcelli, D., Rosso, N., Francavilla, A., Tiribelli, C., and Iolascon, A. 2006. Gene expression analysis in HBV transgenic mouse liver: A model to study early events related to hepatocarcinogenesis. Mol. Med. 12:115‐123.
  Belcher, R., Boyette, J., Pierson, T., Siegel, E., Bartel, T.B., Aniasse, E., and Stack, B. Jr. 2014. What is the role of positron emission tomography in osteonecrosis of the jaws? J. Oral Maxillofacial Surg. 72:306‐310.
  Bettermann, K., Vucur, M., Haybaeck, J., Koppe, C., Janssen, J., Heymann, F., Weber, A., Weiskirchen, R., Liedtke, C., Gassler, N., Muller, M., de Vos, R., Wolf, M.J., Boege, Y., Seleznik, G.M., Zeller, N., Erny, D., Fuchs, T., Zoller, S., Cairo, S., Buendia, M.A., Prinz, M., Akira, S., Tacke, F., Heikenwalder, M., Trautwein, C., and Luedde, T. 2010. TAK1 suppresses a NEMO‐dependent but NF‐kappaB‐independent pathway to liver cancer. Cancer Cell 17:481‐496.
  Bonilla Guerrero, R. and Roberts, L.R. 2005. The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. J. Hepatol. 42:760‐777.
  Bouchard, M.J. and Navas‐Martin, S. 2011. Hepatitis B and C virus hepatocarcinogenesis: Lessons learned and future challenges. Cancer Lett. 305:123‐143.
  Boyault, S., Rickman, D.S., de Reynies, A., Balabaud, C., Rebouissou, S., Jeannot, E., Herault, A., Saric, J., Belghiti, J., Franco, D., Bioulac‐Sage, P., Laurent‐Puig, P., and Zucman‐Rossi, J. 2007. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45:42‐52.
  Caballero, F., Fernandez, A., De Lacy, A.M., Fernandez‐Checa, J.C., Caballeria, J., and Garcia‐Ruiz, C. 2009. Enhanced free cholesterol, SREBP‐2 and StAR expression in human NASH. J. Hepatol. 50:789‐796.
  Chan, H.L., Hui, A.Y., Wong, M.L., Tse, A.M., Hung, L.C., Wong, V.W., and Sung, J.J. 2004. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 53:1494‐1498.
  Cheng, A.L., Kang, Y.K., Chen, Z., Tsao, C.J., Qin, S., Kim, J.S., Luo, R., Feng, J., Ye, S., Yang, T.S., Xu, J., Sun, Y., Liang, H., Liu, J., Wang, J., Tak, W.Y., Pan, H., Burock, K., Zou, J., Voliotis, D., and Guan, Z. 2009. Efficacy and safety of sorafenib in patients in the Asia‐Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double‐blind, placebo‐controlled trial. Lancet Oncol. 10:25‐34.
  Dandri, M. and Petersen, J. 2012. Chimeric mouse model of hepatitis B virus infection. J. Hepatol. 56:493‐495.
  Di Bisceglie, A.M., Shiffman, M.L., Everson, G.T., Lindsay, K.L., Everhart, J.E., Wright, E.C., Lee, W.M., Lok, A.S., Bonkovsky, H.L., Morgan, T.R., Ghany, M.G., Morishima, C., Snow, K.K., and Dienstag, J.L. 2008. Prolonged therapy of advanced chronic hepatitis C with low‐dose peginterferon. New Engl. J. Med. 359:2429‐2441.
  Dunsford, H.A., Sell, S., and Chisari, F.V. 1990. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Res. 50:3400‐3407.
  El‐Serag, H.B. 2007. Epidemiology of hepatocellular carcinoma in USA. Hepatol. Res. 37:S88‐S94.
  El‐Serag, H.B. 2012. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142:1264‐1273 e1.
  Fausto, N. and Campbell, J.S. 2010. Mouse models of hepatocellular carcinoma. Semin. Liver Dis. 30:87‐98.
  Freeman, A.J., Dore, G.J., Law, M.G., Thorpe, M., Von Overbeck, J., Lloyd, A.R., Marinos, G., and Kaldor, J.M. 2001. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 34:809‐816.
  Grivennikov, S.I., Greten, F.R., and Karin, M. 2010. Immunity, inflammation, and cancer. Cell 140:883‐899.
  Guichard, C., Amaddeo, G., Imbeaud, S., Ladeiro, Y., Pelletier, L., Maad, I.B., Calderaro, J., Bioulac‐Sage, P., Letexier, M., Degos, F., Clement, B., Balabaud, C., Chevet, E., Laurent, A., Couchy, G., Letouze, E., Calvo, F., and Zucman‐Rossi, J. 2012. Integrated analysis of somatic mutations and focal copy‐number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genetics 44:694‐698.
  Guidotti, L.G. and Chisari, F.V. 2006. Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. 1:23‐61.
  Haybaeck, J., Zeller, N., Wolf, M.J., Weber, A., Wagner, U., Kurrer, M.O., Bremer, J., Iezzi, G., Graf, R., Clavien, P.A., Thimme, R., Blum, H., Nedospasov, S.A., Zatloukal, K., Ramzan, M., Ciesek, S., Pietschmann, T., Marche, P.N., Karin, M., Kopf, M., Browning, J.L., Aguzzi, A., and Heikenwalder, M. 2009. A lymphotoxin‐driven pathway to hepatocellular carcinoma. Cancer Cell 16:295‐308.
  He, G., Yu, G.Y., Temkin, V., Ogata, H., Kuntzen, C., Sakurai, T., Sieghart, W., Peck‐Radosavljevic, M., Leffert, H.L., and Karin, M. 2010. Hepatocyte IKKbeta/NF‐kappaB inhibits tumor promotion and progression by preventing oxidative stress‐driven STAT3 activation. Cancer Cell 17:286‐297.
  Hebbard, L., Cecena, G., Golas, J., Sawada, J., Ellies, L.G., Charbono, A., Williams, R., Jimenez, R.E., Wankell, M., Arndt, K.T., DeJoy, S.Q., Rollins, R.A., Diesl, V., Follettie, M., Chen, L., Rosfjord, E., Cardiff, R.D., Komatsu, M., Boschelli, F., and Oshima, R.G. 2011. Control of mammary tumor differentiation by SKI‐606 (bosutinib). Oncogene 30:301‐312.
  Heindryckx, F., Colle, I., and Van Vlierberghe, H. 2009. Experimental mouse models for hepatocellular carcinoma research. Int. J. Exp. Pathol. 90:367‐386.
  Hildt, E., Munz, B., Saher, G., Reifenberg, K., and Hofschneider, P.H. 2002. The PreS2 activator MHBs(t) of hepatitis B virus activates c‐raf‐1/Erk2 signaling in transgenic mice. EMBO J. 21:525‐535.
  Huang, S.N. and Chisari, F.V. 1995. Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice. Hepatology 21:620‐626.
  Huynh, H., Pierce Chow, K.H., Soo, K.C., Toh, H.C., Choo, S.P., Foo, K.F., Poon, D., Ngo, V.C., and Tran, E. 2009. RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J. Cell Mol. Med. 13:1371‐1380.
  Hwang, G.Y., Lin, C.Y., Huang, L.M., Wang, Y.H., Wang, J.C., Hsu, C.T., Yang, S.S., and Wu, C.C. 2003. Detection of the hepatitis B virus X protein (HBx) antigen and anti‐HBx antibodies in cases of human hepatocellular carcinoma. J. Clin. Microbiol. 41:5598‐5603.
  Ichibangase, T., Moriya, K., Koike, K., and Imai, K. 2007. A proteomics method revealing disease‐related proteins in livers of hepatitis‐infected mouse model. J. Proteome Res. 6:2841‐2849.
  Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., and Forman, D. 2011. Global cancer statistics. CA Cancer J. Clin. 61:69‐90.
  Jost, P.J. and Kaufmann, T. 2010. Cancer caused by too much apoptosis—an intriguing contradiction? Hepatology 51:1110‐1112.
  Kamegaya, Y., Hiasa, Y., Zukerberg, L., Fowler, N., Blackard, J.T., Lin, W., Choe, W.H., Schmidt, E.V., and Chung, R.T. 2005. Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis. Hepatology 41:660‐667.
  Kawamura, T., Furusaka, A., Koziel, M.J., Chung, R.T., Wang, T.C., Schmidt, E.V., and Liang, T.J. 1997. Transgenic expression of hepatitis C virus structural proteins in the mouse. Hepatology 25:1014‐1021.
  Kim, C.M., Koike, K., Saito, I., Miyamura, T., and Jay, G. 1991. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351:317‐320.
  Kim, H.S., Park, K., Jun, H.J., Yi, S.Y., Lee, J., Ahn, J.S., Park, Y.H., Kim, S., Lee, S., and Ahn, M.J. 2009. Comparison of survival in advanced non‐small cell lung cancer patients in the pre‐ and post‐gefitinib eras. Oncology 76:239‐246.
  Kinzler, K.W. and Vogelstein, B. 1996. Lessons from hereditary colorectal cancer. Cell 87:159‐170.
  Koike, K., Moriya, K., Ishibashi, K., Matsuura, Y., Suzuki, T., Saito, I., Iino, S., Kurokawa, K., and Miyamura, T. 1995. Expression of hepatitis C virus envelope proteins in transgenic mice. J. Gen. Virol. 76:3031‐3038.
  Koike, K., Moriya, K., and Matsuura, Y. 2010. Animal models for hepatitis C and related liver disease. Hepatol. Res. 40:69‐82.
  Lakhtakia, R., Kumar, V., Reddi, H., Mathur, M., Dattagupta, S., and Panda, S.K. 2003. Hepatocellular carcinoma in a hepatitis B 'x' transgenic mouse model: A sequential pathological evaluation. J. Gastroenterol. Hepatol. 18:80‐91.
  Lee, J.S. and Thorgeirsson, S.S. 2002. Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer. Hepatology 35:1134‐1143.
  Lee, J.S., Heo, J., Libbrecht, L., Chu, I.S., Kaposi‐Novak, P., Calvisi, D.F., Mikaelyan, A., Roberts, L.R., Demetris, A.J., Sun, Z., Nevens, F., Roskams, T., and Thorgeirsson, S.S. 2006. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat. Med. 12:410‐416.
  Lerat, H., Honda, M., Beard, M.R., Loesch, K., Sun, J., Yang, Y., Okuda, M., Gosert, R., Xiao, S.Y., Weinman, S.A., and Lemon, S.M. 2002. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 122:352‐365.
  Leveille‐Webster, C.R. and Arias, I.A. 1996. Establishment and serial quantification of intrahepatic xenografts of human hepatocellular carcinoma in severe combined immunodeficiency mice, and development of therapeutic strategies to overcome multidrug resistance. Clin. Cancer Res. 2:695‐706.
  Llovet, J.M. and Hernandez‐Gea, V. 2014. Hepatocellular carcinoma: Reasons for phase III failure and novel perspectives on trial design. Clin. Cancer Res. 20:2072‐2079.
  Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F., de Oliveira, A.C., Santoro, A., Raoul, J.L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T.F., Galle, P.R., Seitz, J.F., Borbath, I., Haussinger, D., Giannaris, T., Shan, M., Moscovici, M., Voliotis, D., Bruix, J., and Group, S.I.S. 2008. Sorafenib in advanced hepatocellular carcinoma. New Engl. J. Med. 359:378‐390.
  Lo, J.C., Wang, Y., Tumanov, A.V., Bamji, M., Yao, Z., Reardon, C.A., Getz, G.S., and Fu, Y.X. 2007. Lymphotoxin beta receptor‐dependent control of lipid homeostasis. Science 316:285‐288.
  Luedde, T., Beraza, N., Kotsikoris, V., van Loo, G., Nenci, A., De Vos, R., Roskams, T., Trautwein, C., and Pasparakis, M. 2007. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11:119‐132.
  Lutgehetmann, M., Mancke, L.V., Volz, T., Helbig, M., Allweiss, L., Bornscheuer, T., Pollok, J.M., Lohse, A.W., Petersen, J., Urban, S., and Dandri, M. 2012. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology 55:685‐694.
  Maeda, S., Kamata, H., Luo, J.L., Leffert, H., and Karin, M. 2005. IKKbeta couples hepatocyte death to cytokine‐driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121:977‐990.
  McMahon, B.J. 2009. The natural history of chronic hepatitis B virus infection. Hepatology 49:S45‐55.
  Midorikawa, Y., Makuuchi, M., Tang, W., and Aburatani, H. 2007a. Microarray‐based analysis for hepatocellular carcinoma: From gene expression profiling to new challenges. World J. Gastroenterol. 13:1487‐1492.
  Midorikawa, Y., Tang, W., and Sugiyama, Y. 2007b. High‐resolution mapping of copy number aberrations and identification of target genes in hepatocellular carcinoma. Bioscience Trends 1:26‐32.
  Moriya, K., Fujie, H., Shintani, Y., Yotsuyanagi, H., Tsutsumi, T., Ishibashi, K., Matsuura, Y., Kimura, S., Miyamura, T., and Koike, K. 1998. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat. Med. 4:1065‐1067.
  Na, B., Huang, Z., Wang, Q., Qi, Z., Tian, Y., Lu, C.C., Yu, J., Hanes, M.A., Kakar, S., Huang, E.J., Ou, J.H., Liu, L., and Yen, T.S. 2011. Transgenic expression of entire hepatitis B virus in mice induces hepatocarcinogenesis independent of chronic liver injury. PloS One 6:e26240.
  Naugler, W.E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A.M., and Karin, M. 2007. Gender disparity in liver cancer due to sex differences in MyD88‐dependent IL‐6 production. Science 317:121‐124.
  Nault, J.C. and Zucman‐Rossi, J. 2014. Genetics of hepatocellular carcinoma: The next generation. J. Hepatol. 60:224‐226.
  Nkongolo, S., Ni, Y., Lempp, F.A., Kaufman, C., Lindner, T., Esser‐Nobis, K., Lohmann, V., Mier, W., Mehrle, S., and Urban, S. 2013. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin‐independent interference with the NTCP receptor. J. Hepatol. 60:723‐731.
  Park, E.J., Lee, J.H., Yu, G.‐Y., He, G., Ali, S.R., Holzer, R.G., Österreicher, C.H., Takahashi, H., and Karin, M. 2010. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL‐6 and TNF expression. Cell 140:197‐208.
  Parkin, D.M. 2006. The global health burden of infection‐associated cancers in the year 2002. Int. J. Cancer 118:3030‐3044.
  Patel, J.D., Krilov, L., Adams, S., Aghajanian, C., Basch, E., Brose, M.S., Carroll, W.L., de Lima, M., Gilbert, M.R., Kris, M.G., Marshall, J.L., Masters, G.A., O'Day, S.J., Polite, B., Schwartz, G.K., Sharma, S., Thompson, I., Vogelzang, N.J., and Roth, B.J. 2014. Clinical cancer advances 2013: Annual report on progress against cancer from the American Society of Clinical Oncology. J. Clin. Oncol. 32:129‐160.
  Pikarsky, E., Porat, R.M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich‐Pyest, E., Urieli‐Shoval, S., Galun, E., and Ben‐Neriah, Y. 2004. NF‐kappaB functions as a tumour promoter in inflammation‐associated cancer. Nature 431:461‐466.
  Pollicino, T., Cacciola, I., Saffioti, F., Raimondoemail, G. 2014. Hepatitis B virus PreS/S gene variants: Pathobiology and clinical implications. J. Hepatol. 61:408‐417.
  Potikha, T., Stoyanov, E., Pappo, O., Frolov, A., Mizrahi, L., Olam, D., Shnitzer‐Perlman, T., Weiss, I., Barashi, N., Peled, A., Sass, G., Tiegs, G., Poirier, F., Rabinovich, G.A., Galun, E., and Goldenberg, D. 2013. Interstrain differences in chronic hepatitis and tumor development in a murine model of inflammation‐mediated hepatocarcinogenesis. Hepatology 58:192‐204.
  Protzer, U., Maini, M.K., and Knolle, P.A. 2012. Living in the liver: Hepatic infections. Nat. Rev. Immunol. 12:201‐213.
  Quasdorff, M. and Protzer, U. 2010. Control of hepatitis B virus at the level of transcription. J. Viral Hepatitis 17:527‐536.
  Renard, C.A., Fourel, G., Bralet, M.P., Degott, C., De La Coste, A., Perret, C., Tiollais, P., and Buendia, M.A. 2000. Hepatocellular carcinoma in WHV/N‐myc2 transgenic mice: Oncogenic mutations of beta‐catenin and synergistic effect of p53 null alleles. Oncogene 19:2678‐2686.
  Ringelhan, M., Heikenwalder, M., and Protzer, U. 2013. Direct effects of hepatitis B virus‐encoded proteins and chronic infection in liver cancer development. Digest. Dis. 31:138‐151.
  Sell, S., Hunt, J.M., Dunsford, H.A., and Chisari, F.V. 1991. Synergy between hepatitis B virus expression and chemical hepatocarcinogens in transgenic mice. Cancer Res. 51:1278‐1285.
  Shi, Y., Wu, Y.H., Wu, W., Zhang, W.J., Yang, J., and Chen, Z. 2012. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta‐analysis. Liver Int. 32:231‐240.
  Slagle, B.L., Lee, T.H., Medina, D., Finegold, M.J., and Butel, J.S. 1996. Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene. Mol. Carcinogenesis 15:261‐269.
  Sprinzl, M.F., Reisinger, F., Puschnik, A., Ringelhan, M., Ackermann, K., Hartmann, D., Schiemann, M., Weinmann, A., Galle, P.R., Schuchmann, M., Friess, H., Otto, G., Heikenwalder, M., and Protzer, U. 2013. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology 57:2358‐2368.
  Sun, F., Tang, Z., and Liu, K. 1995. [Growth pattern and metastatic behaviour of orthotopically metastatic model of human hepatocellular carcinoma in nude mice]. Zhonghua yi xue za zhi 75:673‐675, 710.
  Sun, F.X., Tang, Z.Y., Lui, K.D., Ye, S.L., Xue, Q., Gao, D.M., and Ma, Z.C. 1996. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int. J. Cancer 66:239‐243.
  Terradillos, O., Billet, O., Renard, C.A., Levy, R., Molina, T., Briand, P., and Buendia, M.A. 1997. The hepatitis B virus X gene potentiates c‐myc‐induced liver oncogenesis in transgenic mice. Oncogene 14:395‐404.
  Thorgeirsson, S.S. and Grisham, J.W. 2002. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genetics 31:339‐346.
  Tumanov, A.V., Koroleva, E.P., Christiansen, P.A., Khan, M.A., Ruddy, M.J., Burnette, B., Papa, S., Franzoso, G., Nedospasov, S.A., Fu, Y.X., and Anders, R.A. 2009. T cell‐derived lymphotoxin regulates liver regeneration. Gastroenterology 136:694‐704 e694.
  Vainer, G.W., Pikarsky, E., and Ben‐Neriah, Y. 2008. Contradictory functions of NF‐kappaB in liver physiology and cancer. Cancer Lett. 267:182‐188.
  Villanueva, A. and Llovet, J.M. 2014. Liver cancer in 2013: Mutational landscape of HCC—the end of the beginning. Nat. Rev. Clin. Oncol. 11:73‐74.
  Villanueva, A., Hernandez‐Gea, V., and Llovet, J.M. 2013. Medical therapies for hepatocellular carcinoma: A critical view of the evidence. Nat. Rev. Gastroenterol. Hepatol. 10:34‐42.
  Wang, X., Wang, S., Liu, Y., Ding, W., Zheng, K., Xiang, Y., Liu, K., Wang, D., Zeng, Y., Xia, M., Yang, D., and Wang, Y. 2014. The Hsp90 inhibitor SNX‐2112 induces apoptosis of human hepatocellular carcinoma cells: The role of ER stress. Biochem. Biophys. Res. Comm. 446:160‐166.
  Weber, A. and Heikenwalder, M. 2014. Hepatitis‐B‐ und Hepatitis‐C‐Infektionen: Pathogenese, Diagnostik und Therapie. Onkologie heute 5:22‐25.
  Weber, A., Boger, R., Vick, B., Urbanik, T., Haybaeck, J., Zoller, S., Teufel, A., Krammer, P.H., Opferman, J.T., Galle, P.R., Schuchmann, M., Heikenwalder, M., and Schulze‐Bergkamen, H. 2010. Hepatocyte‐specific deletion of the antiapoptotic protein myeloid cell leukemia‐1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology 51:1226‐1236.
  Weber, A., Boege, Y., Reisinger, F., and Heikenwalder, M. 2011. Chronic liver inflammation and hepatocellular carcinoma: persistence matters. Swiss Med. Weekly 141:w13197.
  Wolf, M.J., Seleznik, G.M., and Heikenwalder, M. 2011. Lymphotoxin's link to carcinogenesis: friend or foe? from lymphoid neogenesis to hepatocellular carcinoma and prostate cancer. Adv. Exp. Med. Biol. 691:231‐249.
  Wolf, M.J., Seleznik, G.M., Zeller, N., and Heikenwalder, M. 2010. The unexpected role of lymphotoxin beta receptor signaling in carcinogenesis: From lymphoid tissue formation to liver and prostate cancer development. Oncogene 29:5006‐5018.
  World Health Organization. 2012. Hepatitis B. http://www.who.int/mediacentre/factsheets/fs204/en/.
  Yan, H., Zhong, G., Xu, G., He, W., Jing, Z., Gao, Z., Huang, Y., Qi, Y., Peng, B., Wang, H., Fu, L., Song, M., Chen, P., Gao, W., Ren, B., Sun, Y., Cai, T., Feng, X., Sui, J., and Li, W. 2012. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 1:e00049.
  Yan, M., Li, H., Zhao, F., Zhang, L., Ge, C., Yao, M., and Li, J. 2013. Establishment of NOD/SCID mouse models of human hepatocellular carcinoma via subcutaneous transplantation of histologically intact tumor tissue. Chin. J. Cancer Res. 25:289‐298.
  Yu, D.Y., Moon, H.B., Son, J.K., Jeong, S., Yu, S.L., Yoon, H., Han, Y.M., Lee, C.S., Park, J.S., Lee, C.H., Hyun, B.H., Murakami, S., and Lee, K.K. 1999. Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X‐protein. J. Hepatol. 31:123‐132.
  Zucman‐Rossi, J. 2010. Molecular classification of hepatocellular carcinoma. Digest. Liver Dis. 42:S235‐S241.
  Zucman‐Rossi, J., Jeannot, E., Nhieu, J.T., Scoazec, J.Y., Guettier, C., Rebouissou, S., Bacq, Y., Leteurtre, E., Paradis, V., Michalak, S., Wendum, D., Chiche, L., Fabre, M., Mellottee, L., Laurent, C., Partensky, C., Castaing, D., Zafrani, E.S., Laurent‐Puig, P., Balabaud, C., and Bioulac‐Sage, P. 2006. Genotype‐phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC. Hepatology 43:515‐524.
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library